“Phase three trials are about efficacy. Approving something without knowing it works would be a terrible mistake. I sure hope the FDA does not do this… we want to develop a vaccine safely and effectively and if we don’t do that, we will have a problem,” says Dr. Carlos del Rio, an epidemiologist and executive associate dean of Emory University School of Medicine.